Physician profile
Dowell Mullins
NPI 1992796346
$592.53
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $263 · 2020: $95.12 · 2021: $58.41 · 2022: $176.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $217.48 | 2019-2021 | |
| Abbvie INC. | $129.12 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $124.83 | 2019 | |
| Exeltis, USA INC. | $94.76 | 2022 | |
| Ascend Therapeutics US, LLC | $14.45 | 2022 | |
| Axonics, INC. | $11.89 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dowell Mullins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.